Guillain-Barre syndrome following COVID-19 vaccination: a case report and an updated review.

To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection

“…This may have increased the number of recorded relapses. Fourth, in vaccine safety studies, the 28 to even 60-day risk intervals in the search for autoimmune neurological adverse events are often used because of the dynamics of immune response ( Aly et al., 2022 ; Confavreux et al., 2001 ; Kim et al., 2022 ; Lee et al., 2011 ; Li et al., 2022 ; Watad et al., 2021 ). For the most widely used vaccine in Czechia (BNT162b2), the recommended interval between vaccine doses was 38–42 days, later replaced by 21 days.…”

Recombinant protein subunit COVID‐19 vaccine‐induced Guillain‐Barré Syndrome in an adolescent: A case report

“… 17 Several case reports have been published in the past year showing a possible link between GBS and adenoviral COVID‐19 vaccines. 3 , 4 , 5 , 6 , 7 In the cohort study of surveillance data from the Vaccine Safety Datalink, which included data on 15.1 million doses of COVID‐19 vaccines from nine United States integrated healthcare systems and the CDC, the occurrence of GBS within 3 weeks of receiving the Janssen adenoviral COVID‐19 vaccine was 32.4 per 100 000 person‐years, which was significantly higher than the background incidence of 1–2 per 100 000 person‐years in adults. In contrast, the incidence of GBS following mRNA‐based vaccines was 1.3 per 100 000 person‐years.…”

“…GBS, or acute inflammatory demyelinating polyneuropathy (AIDP), is a neurological autoimmune condition that has been reported as a rare adverse event following COVID‐19 vaccination in adults. 3 , 4 , 5 , 6 , 7 On 22 July 2021, the European Medicines Agency (EMA) issued a statement that GBS should be listed as a very rare adverse effect of adenovirus COVID‐19 vaccine and that a warning should be included in the vaccine information to raise awareness among concerned health care professionals and individuals receiving the recombinant adenovirus COVID‐19 vaccine. 8 Subsequently, the Global Advisory Committee on Vaccine Safety (GACVS) COVID‐19 subcommittee recommended that health care professionals and individuals receiving COVID‐19 vaccines from Janssen or AstraZeneca should be alerted and if clinical signs and symptoms suggestive of GBS develop, they should seek immediate medical care.…”

“…Despite reported high efficacy and satisfactory safety of COVID‐19 vaccines in clinical trials, there is a possibility of rare side effects going undetected in the clinical trials given their inherent limitations. GBS, or acute inflammatory demyelinating polyneuropathy (AIDP), is a neurological autoimmune condition that has been reported as a rare adverse event following COVID‐19 vaccination in adults 3–7 . On 22 July 2021, the European Medicines Agency (EMA) issued a statement that GBS should be listed as a very rare adverse effect of adenovirus COVID‐19 vaccine and that a warning should be included in the vaccine information to raise awareness among concerned health care professionals and individuals receiving the recombinant adenovirus COVID‐19 vaccine 8 .…”

“…GBS, or acute inflammatory demyelinating polyneuropathy (AIDP), is a neurological autoimmune condition that has been reported as a rare adverse event following COVID-19 vaccination in adults. [3][4][5][6][7] On 22 July 2021, the European Medicines Agency (EMA) issued a statement that GBS should be listed as a very rare adverse effect of adenovirus COVID-19 vaccine and that a warning should be included in the vaccine information to raise awareness among concerned Rachna Rohilla and Ashish Kumar Kakkar contributed equally as first authors.…”